Last updated: May 27, 2026
Invega Sustenna (paliperidone palmitate) suppliers: Who manufactures, fills, and supplies the drug product and key components?
Invega Sustenna is a long-acting injectable (LAI) antipsychotic with a controlled-release formulation of paliperidone palmitate. The drug product supply chain is typically organized around (1) drug substance (API) manufacturers for paliperidone palmitate, (2) sterile injectable fill-finish sites that produce and package the syringes or kits, and (3) secondary packaging and distribution under the marketing authorization holder.
Because the name “supplier” is used across business contexts (API source, finished-dose fill-finish site, or distributor), the actionable map below is structured as manufacturing roles tied to regulated submissions (US FDA, EMA) rather than retail “vendors.”
Who makes Invega Sustenna drug substance (paliperidone palmitate) and where?
Featured snippet answer: The paliperidone palmitate drug substance for Invega Sustenna is manufactured at one or more commercial API sites that appear in FDA manufacturing information (commonly via Drug Master File references and/or US NDA chemistry manufacturing and controls disclosures). The exact site list is tied to the specific BLA/NDA and supplement history for the product strength and packaging configuration.
Drug substance supply roles
Common regulated roles for API supply include:
- API synthesis and isolation for paliperidone palmitate.
- Particle/solid-state control activities that materially affect LAI performance (crystal form, PSD, residual solvents).
- Quality release under GMP with batch traceability to product lots.
What to check in regulatory listings
For “who supplies,” the operational method is to extract:
- API manufacturing sites listed in FDA CMC sections for the product NDA.
- DMF holders referenced by the NDA for paliperidone palmitate.
- Cross-walk between US and EU manufacturing authorizations (EMA Article 57 lists and public assessment documents).
Which companies do fill-finish for Invega Sustenna syringes (sterile manufacturing and packaging)?
Featured snippet answer: Invega Sustenna uses a sterile injectable format that requires aseptic filling into prefilled syringes and subsequent packaging. The fill-finish manufacturer(s) are typically listed as responsible manufacturing sites in FDA “Manufactured for” and site-specific labeling, plus in EU GMP manufacturing authorization entries.
Fill-finish scope for LAI suspensions
Manufacturing steps that determine supplier selection include:
- Sterile filtration and aseptic processing for suspension products.
- Homogeneity and suspension stability controls during filling.
- Container-closure system validation for prefilled syringes.
- Strength-specific fill volume and label configuration.
How supply risk shows up for LAIs
Fill-finish constraints for LAIs often correlate with:
- Single-site reliance for syringe filling lines.
- Limited capacities for specific syringe sizes and elastomer/plunger systems.
- Tight release specs for particle attributes and residuals.
What is the official marketing authorization holder (MAH) and how does that map to suppliers?
Featured snippet answer: The MAH and label holder for Invega Sustenna is Janssen (Janssen Biotech / Janssen Pharmaceutica, depending on territory and filing). The MAH contracts with one or more GMP sites for API, sterile manufacturing, and packaging, and the contracted sites appear in regulatory manufacturing disclosures.
Why MAH matters for procurement
From a licensing and procurement standpoint, the MAH drives:
- Contract manufacturing qualification.
- Stability program ownership.
- Batch release decisions and pharmacovigilance batch tracking.
Which global suppliers appear across US (FDA) and EU (EMA) manufacturing listings for Invega Sustenna?
Featured snippet answer: The supplier list for Invega Sustenna differs by region because:
- US and EU authorizations use different submission structures.
- Sites can be added via CMC supplements.
- EU often uses named GMP manufacturing authorization holders and sites, while US uses NDA labeling and CMC listings.
Region-specific procurement impacts
- US: FDA labeling and CMC disclosures govern the readily auditable “manufactured at” sites.
- EU: EMA public assessment and GMP authorization records govern the auditable manufacturing sites.
What patent estate structure affects suppliers of generic or “authorized” Invega Sustenna products?
Featured snippet answer: Suppliers of generic LAIs face constraints from a layered patent estate: formulation/particle specification, manufacturing process, and method-of-use protection. For procurement strategy, supplier selection often depends on whether the supplier can design around or license key patents.
Patent estate dimensions that drive supplier choices
- Formulation patents covering the suspension characteristics (paliperidone palmitate formulation, stabilizers, rheology).
- Manufacturing method patents (milling, mixing order, aging, sterile processing steps).
- Device/container-closure and delivery system patents.
(If you are targeting an actionable “supplier to contest” list, it depends on the specific patent families asserted against each LAI competitor in the US ANDA/505(b)(2) pathway.)
Do Invega Sustenna suppliers change by strength (25 mg, 50 mg, 75 mg, 100 mg)?
Featured snippet answer: Yes. LAI products frequently use shared production steps but may have:
- strength-specific fills,
- strength-specific packaging,
- and occasionally separate equipment configurations.
Supplier mapping should be done by strength and pack configuration using lot-level labeling and regulatory manufacturing site lists.
How to identify the exact Invega Sustenna supplier per lot (most reliable procurement method)
Featured snippet answer: Use the lot number on the commercial carton and syringe label and match it to:
- the manufacturing site indicated in label text (site-specific “manufactured for”),
- and the regulatory listing for that NDA product/strength.
Procurement-grade matching workflow
- Record the label’s manufacturing site and lot number.
- Pull the corresponding product listing for the NDA strength and packaging configuration.
- Map to:
- API supplier (DMF/CMC references),
- fill-finish site (aseptic and packaging),
- and secondary packaging/distribution (often less constrained).
This avoids misleading “supplier” names that appear in distributor catalogs.
Key Takeaways
- “Suppliers” for Invega Sustenna must be separated into API (drug substance), aseptic fill-finish, and secondary packaging/distribution roles.
- The authoritative supplier list is the one tied to FDA labeling and CMC manufacturing disclosures (US) and EMA GMP authorization entries (EU), not retail distributor listings.
- LAI supply is strength-sensitive and may shift with CMC supplements and capacity reassignments.
- For generic/authorized entry or licensing strategy, the relevant supplier pool depends on the patent estate segments that constrain formulation and manufacturing design.
FAQs
- Is paliperidone palmitate for Invega Sustenna made by the same company that fills the prefilled syringes?
- How can I confirm the Invega Sustenna manufacturing site from a specific lot number?
- Do the fill-finish suppliers for Invega Sustenna differ between US and EU?
- What supplier capabilities are required for LAI sterile filling of suspension products like Invega Sustenna?
- How does the Invega Sustenna patent estate affect supplier eligibility for generic LAI projects?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drug label for Invega Sustenna (paliperidone palmitate) (accessed via FDA label and product listing).
- European Medicines Agency. (n.d.). Invega Sustenna (paliperidone palmitate) product information and EPAR/assessment documentation (accessed via EMA public records).
